Showing results (171-180 of 181) with videos related to
Sort By:
Pageof 19
European Urology Focus|June 18, 2022
Effect of Levofloxacin on the Efficacy and Adverse Events in Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer: Results of a Randomized, Prospective, Multicenter StudyKazuyuki Numakura, Mizuki Kobayashi, Toshiya Ishida, et al.Journal of Clinical Pathology|May 8, 2020
Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomasMitsuko Furuya, Yasuhiro Iribe, Yoji Nagashima, et al.Iscience|April 8, 2020
Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor ModelSoki Kashima, Takuya Maeda, Kyoko Masuda, et al.Cancer Research and Treatment|June 27, 2025
Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 StudySe Hoon Park, Yen-Hwa Chang, Jae Lyun Lee, et al.Japanese Journal of Clinical Oncology|February 2, 2025
Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective studyHiroshi Kikuchi, Takahiro Osawa, Yuto Matsushita, et al.Cancers|April 13, 2023
Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCGKazuyuki Numakura, Makito Miyake, Mizuki Kobayashi, et al.Japanese Journal of Clinical Oncology|November 17, 2023
The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin therapyHiroshi Kikuchi, Takashige Abe, Makito Miyake, et al.BMC Cancer|March 12, 2021
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative studyMakito Miyake, Kota Iida, Nobutaka Nishimura, et al.The Prostate|September 30, 2024
Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapyShintaro Narita, Takafumi Yanagisawa, Shingo Hatakeyama, et al.Clinical Genitourinary Cancer|March 21, 2025
Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell CarcinomaMasayuki Takahashi, Yuto Matsushita, Takahiro Kojima, et al.Pageof 19